Distinguished in Gastroesophageal Junction Cancer

Ken Kato

Chiba, JP 
Distinguished in Gastroesophageal Junction Cancer
Chiba, JP 
OverviewLocationsClinical Research

Overview

Ken Kato practices in Chiba, Japan. Mr. Kato is rated as a Distinguished expert by MediFind in the treatment of Gastroesophageal Junction Cancer. His top areas of expertise are Esophageal Cancer, Gastroesophageal Junction Cancer, Stomach Cancer, Cardiac Ablation, and Endoscopy.

His clinical research consists of co-authoring 568 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 21 articles in the study of Gastroesophageal Junction Cancer.

Gender
Male

Locations

Chiba, Japan
Other Locations
Tokyo, Japan
Chuo, Japan
Fuchu, Japan
Kurume, Japan
Chuo, 2608677, Japan
Sapporo, Japan
Department Of Head And Neck, Chuo, Japan
Zama, 2528583, Japan
Nagano, Japan
Tsukiji, 1040045, Japan
Sayama, Japan
Nagoya, Japan
Saitama, Japan
Kawahara, 6068507, Japan
Japan
Kawagoe, 3501165, Japan
Showa, Japan
Toyoake, Japan
Sumiyoshi, 5588585, Japan
Kyoto, 1040045, Japan
Higashihara, 2528583, Japan
Sayo, 6795148, Japan
Toyooka, Japan
Yushima, 1138519, Japan
Shinjuku, 1628666, Japan
Nakamichi, 5378511, Japan
Okazaki, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Biological
Study Drugs: Cisplatin, Capecitabine, Paclitaxel, Fluorouracil (5-FU), Oxaliplatin, Tislelizumab
Study Phase: Phase 3

568 Total Publications

Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan.
Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan.
Journal: JCO precision oncology
Published: January 15, 2026

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kato's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 79 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile